Customer No.: 31846

In the Claims

1. (Original) A contraceptive and/or HRT kit comprising a

contraceptively and/or therapeutically effective amount of a

long-acting etonogestrel ester with a fatty-chain length of C7-

C15.

2. (Currently Amended) A  $\underline{\text{The}}$  kit according to claim 1, wherein

the etonogestrel ester is etonogestrel undecancate and/or

etonogestrel decanoate and/or etonogestrel dodecanoate.

3. (Currently Amended) A  $\underline{\text{The}}$  kit according to claim 1, or 2

further comprising a contraceptively and/or therapeutically

effective amount of an androgen ester.

4. (Currently Amended) A The kit according to claim 3, wherein

the androgen ester is MENT undecanoate.

5. (Currently Amended) A The kit according to claim 4, wherein

the contraceptively and/or therapeutically effective amount of

MENT undecanoate is 50-400 mg and the contraceptively and/or

therapeutically effective amount of etonogestrel ester is 25-200

mg.

-4-

Customer No.: 31846

6. (Currently Amended) A  $\underline{\text{The}}$  kit according to claim  $5_{\underline{\prime}}$  wherein

the contraceptively and/or therapeutically effective amount of

MENT undecanoate is 50-200 mg and the contraceptively and/or

therapeutically effective amount of etonogestrel ester is 50-100

mg.

7. (Currently Amended) A  $\underline{\text{The}}$  kit according to claim  $6_{\underline{\prime}}$  wherein

the contraceptively and/or therapeutically effective amount of

MENT undecanoate is 100 mg and the contraceptively and/or

therapeutically ettective amount of etonogestrel ester is 50 mg.


8. (Currently Amended) A  $\underline{\text{The}}$  kit according to claim  $1_{\underline{\prime}}$  or 2

further comprising a contraceptively and/or therapeutically

effective amount of an estrogen.

- 9. (Canceled).
- 10. (Canceled).
- 11. (Canceled).
- 12. (Canceled).

Attorney Docket No.: O-2002.732 US Customer No.: 31846



18. (Currently Amended) A method of contraception and/or HRT, comprising:

administering to a subject a contraceptively and/or therapeutically effective amount of a long acting etonogestrel ester with a fatty-chain length of C7-C15.

19. (Currently Amended) A The method according to claim 18, wherein the ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate.

Customer No.: 31846

20. (Currently Amended) A  $\underline{\text{The}}$  method according to claim 18,

wherein a contraceptively and/or therapeutically effective amount

of a long-acting androgen ester is administered in conjunction

with the etonogestrel ester.

21. (Currently Amended) A The method according to claim 20,

wherein the etonogestrel ester is etonogestrel undecanoate and/or

etonogestrel decanoate and/or etonogestrel dodecanoate and the

androgen ester is MENT undecanoate.

22. (Currently Amended) A The method according to claim 21,

wherein the contraceptively and/or therapeutically effective

amount of MENT undecanoate is 50-400 mg and the contraceptively

and/or therapeutically effective amount of etonogestrel ester is

25-200 mg.

23. (Currently Amended) A The method according to claim 22,

wherein the contraceptively and/or therapeutically effective

amount of MENT undecanoate is 50-200 mg and the contraceptively

and/or therapeutically effective amount of etonogestrel ester is

50-100 mg.

24. (Currently Amended) A The method according to claim 23,

-7-

Customer No.: 31846

wherein the contraceptively and/or therapeutically effective

amount of MENT undecanoate is 100 mg and the contraceptively

and/or therapeutically effective amount of etonogestrel ester is

50 mg.

25. (Currently Amended) A  $\underline{\text{The}}$  method according to claim 18, or 19

wherein a contraceptively and/or therapeutically effective amount

of an estrogen is administered in conjunction with the

etonogestrel ester.

26. (Canceled).

27. (Canceled).

28. (Canceled).

29. (Currently Amended) A method of treating and/or preventing a

female gynaecological gynecological disorder, comprising:

administering to a female subject a therapeutically

effective amount of a long-acting etonogestrel ester with a

fatty-chain length of C7-C15 effective to treat and/or prevent

the disorder.

-8-

Customer No.: 31846

30. (Currently Amended) A The method according to claim 29, wherein the etonogestrel ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecaneate.

31. (Currently Amended) A The method according to claim 29, or 30 wherein the female gynaecological gynecological disorder is selected from the group consisting of endometriosis, menorrhagia, meno-metrorrhagia, pre-menstrual syndrome and dysmenorrhoea.